Despite the lack of a stratification method with high molecular precision in the clinic, anti-PD1 therapy is being tested in clinical trials to prevent recurrence and progression of high-risk NMIBC after tumor resection, as well as in conjunction with BCG therapy in a pre-surgical setting [81]. Here, PDCD1 is linked to neoplasm.